Loading...
XLONAPH
Market cap310mUSD
Jan 07, Last price  
46.00GBP
1D
0.22%
1Q
5.50%
Jan 2017
-2.91%
Name

Alliance Pharma PLC

Chart & Performance

D1W1MN
XLON:APH chart
P/E
—
P/S
137.62
EPS
—
Div Yield, %
0.04%
Shrs. gr., 5y
1.14%
Rev. gr., 5y
8.86%
Revenues
181m
+7.92%
11,826,00012,276,00017,253,00018,224,00021,757,00031,237,00049,881,00045,957,00044,897,00045,513,00043,536,00048,344,00097,492,000103,315,000118,208,000135,637,000129,801,000163,207,000167,416,000180,680,000
Net income
-33m
L
407,000661,000503,000-3,210,0002,511,0004,107,0008,954,0008,636,0008,690,0009,584,0008,385,00012,692,00018,092,00028,910,00018,356,00025,010,0008,027,0007,319,000936,000-33,136,000
CFO
31m
+49.77%
-253,000360,000-910,0001,703,0002,616,0007,694,00014,895,0008,719,00012,435,00010,030,00011,423,0007,976,00016,925,00026,583,00022,170,00035,758,00041,567,00038,659,00020,972,00031,410,000
Dividend
Jun 22, 20231.184 GBP/sh
Earnings
May 06, 2025

Profile

Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
URL
https://www.alliancepharmaceuticals.com/
IPO date
Nov 22, 2001
Employees
285
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
180,680
7.92%
167,416
2.58%
Cost of revenue
129,880
129,319
Unusual Expense (Income)
NOPBT
50,800
38,097
NOPBT Margin
28.12%
22.76%
Operating Taxes
(15,664)
4,272
Tax Rate
11.21%
NOPAT
66,464
33,825
Net income
(33,136)
-3,640.17%
936
-87.21%
Dividends
(9,592)
(9,116)
Dividend yield
Proceeds from repurchase of equity
37
341
BB yield
Debt
Debt current
768
613
Long-term debt
120,416
137,576
Deferred revenue
Other long-term liabilities
1,970
3,415
Net debt
98,671
106,458
Cash flow
Cash from operating activities
31,410
20,972
CAPEX
(696)
(607)
Cash from investing activities
(918)
(17,025)
Cash from financing activities
(39,193)
(876)
FCF
49,368
17,554
Balance
Cash
22,436
31,714
Long term investments
77
17
Excess cash
13,479
23,360
Stockholders' equity
48,770
136,011
Invested Capital
323,779
399,089
ROIC
18.39%
8.69%
ROCE
13.54%
7.81%
EV
Common stock shares outstanding
540,145
545,281
Price
Market cap
EV
EBITDA
61,126
48,857
EV/EBITDA
Interest
9,991
4,785
Interest/NOPBT
19.67%
12.56%